Patents by Inventor Barrett Rollins

Barrett Rollins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Suppressing tumor formation using cells expressing JE/monocyte chemoattractant protein-1
    Patent number: 6767535
    Abstract: A method of suppressing tumor formation in a vertebrate by administering JE/MCP-1 is described. Also described are methods of treating localized complications of malignancies and methods of combatting parasitic infection by administering JE/MCP-1.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: July 27, 2004
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Barrett Rollins, Charles Stiles
  • Chemokine N-terminal deletion mutations
    Patent number: 5854412
    Abstract: The invention relates to mutant chemokines and pharmaceutical compositions thereof, wherein the mutant inhibits the corresponding endogenous chemokine from binding or activating a responsive receptor. The claimed mutant chemokines can be administered to a patient for the treatment or prophylaxis of a chemokine-mediated disease. The invention further relates to isolated DNAs encoding the mutant chemokines, vectors and recombinant host cells containing the same.
    Type: Grant
    Filed: October 23, 1997
    Date of Patent: December 29, 1998
    Assignee: Dana-Farber Cancer Institute
    Inventors: Barrett Rollins, Yujun Zhang
  • Chemokine N-terminal deletion mutations
    Patent number: 5739103
    Abstract: The invention relates to mutant chemokines and pharmaceutical compositions thereof, wherein the mutant inhibits the corresponding endogenous chemokine from binding or activating a responsive receptor. The claimed mutant chemokines can be administered to a patient for the treatment or prophylaxis of a chemokine-mediated disease. The invention further relates to isolated DNAs encoding the mutant chemokines, vectors and recombinant host cells containing the same.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: April 14, 1998
    Assignee: Dana-Farber Cancer Institute
    Inventors: Barrett Rollins, Yujun Zhang
  • Chemokine N-terminal deletion mutations
    Patent number: 5705360
    Abstract: The invention relates to mutant chemokines and pharmaceutical compositions thereof, wherein the mutant inhibits the corresponding endogenous chemokine from binding or activating a responsive receptor. The claimed mutant chemokines can be administered to a patient for the treatment or prophylaxis of a chemokine-mediated disease. The invention further relates to isolated DNAs encoding the mutant chemokines, vectors and recombinant host cells containing the same.
    Type: Grant
    Filed: July 16, 1996
    Date of Patent: January 6, 1998
    Assignee: Dana-Farber Cancer Institute
    Inventors: Barrett Rollins, Yujun Zhang
  • Human monocyte chemoattractant protein-1 (MCP-1) derivatives
    Patent number: 5459128
    Abstract: The invention relates to a human MCP-1 derivative, and pharmaceutical compositions thereof, wherein human MCP-1 has been modified such that the protein inhibits monocyte chemoattractant activity. Successful inhibition of the activity is found where the MCP-1 is modified in one or more of the following: a) the 28-tyrosine is substituted by aspartate, b) the 24-arginine is substituted by phenylalanine, c) the 3-aspartate is substituted by alanine, and/or d) the 2-8 amino acid sequence is deleted. The claimed MCP-1 derivatives can be administered to a patient in need of inhibiting MCP-1 monocyte chemoattractant activity. For example, the derivatives can be used to prevent restenosis, such as that which is common in a patient undergoing coronary artery angioplasty. The invention further relates to compositions and methods of inhibiting monocyte chemoattractant activity of MCP-1 employing the derivatives described.
    Type: Grant
    Filed: October 27, 1994
    Date of Patent: October 17, 1995
    Assignee: Dana-Farber Cancer Institute
    Inventors: Barrett Rollins, Yu J. Zhang
  • Human cytokine
    Patent number: 5278287
    Abstract: A novel human cytokine, JE factor, and processes for producing it are disclosed. JE may be used in pharmaceutical preparations for stimulating and/or enhancing immune responsiveness and in wound healing and related tissue repair. containing the factor.
    Type: Grant
    Filed: April 13, 1993
    Date of Patent: January 11, 1994
    Assignees: Genetics Institute, Inc., Dana-Farber Cancer Institute
    Inventors: Barrett Rollins, Charles Stiles, Gordon G. Wong
  • Process for producing human JE cytokine
    Patent number: 5212073
    Abstract: A novel human cytokine, JE factor, and processes for producing it are disclosed. JE may be used in pharmaceutical preparations for stimulating and/or enhancing immune responsiveness and in wound healing and related tissue repair.
    Type: Grant
    Filed: May 12, 1989
    Date of Patent: May 18, 1993
    Assignees: Genetics Institute, Inc., Dana Farber Cancer Inst.
    Inventors: Barrett Rollins, Charles Stiles, Gordon G. Wong
  • Method of suppressing tumor formation in vivo
    Patent number: 5179078
    Abstract: A method of suppressing tumor formation in a vertebrate by administering JE/MCP-1 is described. Also described are methods of treating localized complications of malignancies and methods of combatting parasitic infection by administering JE/MCP-1.
    Type: Grant
    Filed: May 16, 1991
    Date of Patent: January 12, 1993
    Assignee: Dana Farber Cancer Institute
    Inventors: Barrett Rollins, Charles Stiles